
LFCR Stock Forecast & Price Target
LFCR Analyst Ratings
Bulls say
Lifecore Biomedical Inc. is poised for growth, evidenced by an increase in EBITDA from $22.6 million with a 16.8% margin in FY26 to an anticipated $27.3 million with a 19.1% margin in FY27. Additionally, the company has successfully transitioned to positive free cash flow, projecting $5.1 million in FY26, which is expected to rise to $6.0 million in FY27. This combination of expanding margins and strengthening cash flow underlines a robust financial outlook for Lifecore Biomedical.
Bears say
Lifecore Biomedical Inc faces a challenging financial outlook due to an anticipated decline in market growth for fill/finish services, projected to be lower than the company's stated 10% growth assumption. Additionally, the company is experiencing a high leverage ratio, which further complicates its financial position and suggests increased risk. These factors, combined with a lack of meaningful revenue growth expected until calendar year 2027, justify a cautious perspective on the company's stock performance compared to its peers.
This aggregate rating is based on analysts' research of Lifecore Biomedical Inc and is not a guaranteed prediction by Public.com or investment advice.
LFCR Analyst Forecast & Price Prediction
Start investing in LFCR
Order type
Buy in
Order amount
Est. shares
0 shares